Aristolochic acid
This article was originally published in The Tan Sheet
Executive Summary
FDA reiterates plea for health professionals to review cases of "unexplained" renal disease, urothelial tract tumors to determine if patients used supplements. In statement published in June 6 JAMA, Acting Principal Deputy Director Bernard Schwetz, PhD, says related cases should be reported "as soon as possible" to agency's MedWatch program. FDA outlined concerns regarding aristolochic acid-containing supplements in three separate letters to health professionals, consumers and industry in early April (1"The Tan Sheet" April 16, p. 9)
You may also be interested in...
Aristolochic acid
Thirteen Treasure of the East products containing herb linked to kidney failure and increased cancer risk recalled by Ithaca, N.Y.-based Blue Light, FDA announces June 20. Total of 1,213 bottles of powder or capsules distributed nationwide, mainly to specialty retailers and herbal practitioners; no illnesses have been reported, agency notes. FDA Acting Principle Deputy Director Bernard Schwetz, PhD, recently asked health professionals to assist in cataloging renal adverse events possibly related to ingestion of frequently recalled herb (1"The Tan Sheet" June 11, In Brief)
Aristolochic acid
Thirteen Treasure of the East products containing herb linked to kidney failure and increased cancer risk recalled by Ithaca, N.Y.-based Blue Light, FDA announces June 20. Total of 1,213 bottles of powder or capsules distributed nationwide, mainly to specialty retailers and herbal practitioners; no illnesses have been reported, agency notes. FDA Acting Principle Deputy Director Bernard Schwetz, PhD, recently asked health professionals to assist in cataloging renal adverse events possibly related to ingestion of frequently recalled herb (1"The Tan Sheet" June 11, In Brief)
Aristolochic acid
Thirteen Treasure of the East products containing herb linked to kidney failure and increased cancer risk recalled by Ithaca, N.Y.-based Blue Light, FDA announces June 20. Total of 1,213 bottles of powder or capsules distributed nationwide, mainly to specialty retailers and herbal practitioners; no illnesses have been reported, agency notes. FDA Acting Principle Deputy Director Bernard Schwetz, PhD, recently asked health professionals to assist in cataloging renal adverse events possibly related to ingestion of frequently recalled herb (1"The Tan Sheet" June 11, In Brief)